Investing.comDoubao · 实盘不做把握 5/10不做原因:风险收益比不佳
北京时间·🕒 发布 15:04:35·⟳ 抓取 15:05:02 +27s·⚡ 决策 10-19 16:31:22 +1h26m·8.2 天前
Evaxion 公布个性化黑色素瘤疫苗 EVX-01 二期三年随访数据：6 名延续期患者全部维持应答、无进展
方向偏正面但属确认性、低增量的早期临床更新：延续期仅 6 人、无新 ORR/OS 数据，三年读出时点早在 7 月 17 日即已预告；盘前已约 +10% 重定价，而 EVAX 是日均成交约 14 万美元的纳微盘，盘前成交仅数千股、bid-ask 价差约 6%，追入滑点与 ESMO 见光死风险远大于剩余 edge。
📄 原文Investing.com↗ 原文
Evaxion reports three-year data for melanoma vaccine EVX-01
Oil prices slide 2% as Trump waives Russia sanctions COPENHAGEN - Evaxion A/S (NASDAQ:EVAX) announced three-year clinic…
不做 Evaxion A/S（EVAX.US）
确认性耐久更新（延续期仅 6 人、无新增疗效量级）且读出时点 7 月已预告，预期差小；盘前已涨约 10%，但市值仅约 2,550 万美元、日均成交约 14 万美元、盘前价差约 6%，追入滑点大且 10 月 23 日 ESMO 完整数据有见光死风险，无正期望；不存在 A/H 股同权益或供应链映射标的
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
EVX-01 三年随访确认 6 名延续期患者全部维持应答，叙事正面但只是对 2025 年两年强数据的耐久性确认、样本极小；盘前已涨约 10% 且标的极度低流动性，10 月 23 日 ESMO 完整数据前追高风险收益比不佳，不做。
消息传播链
- 公司正式发布三年随访结果：6 名进入单药延续期的患者全部维持应答、无肿瘤进展；完整数据留待 ESMO 口头报告
- AI 辅助生成的转述稿，无新增事实，传播范围有限
关键理由
- 单药延续期全员维持应答、无进展，支持疫苗诱导免疫记忆的持久性叙事，对平台估值有边际正面作用
- ESMO 口头报告（10 月 23 日）临近，存在完整数据催化窗口
主要风险
- 延续期仅 6/12 名应答者、无随机对照，本质是确认性更新而非新疗效证据，且 7 月已预告读出时点，预期差有限
- EVAX 市值约 2,550 万美元、20 日日均成交额仅约 14 万美元，盘前价差宽、量极薄，ESMO 完整数据若不及标题预期易见光死且难以离场
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-19 · 影响 weakens
进入单药延续期仅 6 人（12 名应答者中），通稿未给新的 PFS/OS/对照数据，完整疗效与安全性需等 10 月 23 日 ESMO 口头报告；无 BD/授权或注册路径新信息
检索:Evaxion EVX-01 phase 2 extension cohort size safety ESMO 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-20 · 影响 weakens
公司为临床前收入阶段（PE 为负），市值约 2,550 万美元、股价较 52 周高点回撤约 75%，存在持续融资/摊薄风险，20 日跌 13.5%
检索:EVAX stock cash runway dilution financing 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺失与小样本、低流动性共同支持不追高、回避，而非降低仓位 ENTER
方向:未运行历史先例统计：本次结论由低增量确认性数据、盘前已约 +10% 的即时反应和极端流动性不足直接支撑，不依赖先例幅度
涨幅量级:无对齐先例校准止盈区间；在微盘、薄量、ESMO 见光死风险下不具备设定正期望 tp/sl 的基础
形态:临床期小盘股常见'会议前数据预告上涨、口头报告见光死'模式，但本次未以真实先例量化
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`evaxion evax personalized cancer vaccine esmo 2026 3-year follow-up | evaxion evx-01 three-year data melanoma phase 2`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - web_search 成功 doubao_search · 1,597 ms
豆包搜索结果（原始查询:Evaxion EVX-01 three-year data melanoma press release October 2026；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 144 ms
{
原文全文
展开原文 · 2,085 字
Oil prices slide 2% as Trump waives Russia sanctions
COPENHAGEN - Evaxion A/S (NASDAQ:EVAX) announced three-year clinical data from its phase 2 trial of personalized cancer vaccine EVX-01 in patients with advanced melanoma, according to a press release statement.
All patients at three-year follow-up maintained clinical responses observed at two-year follow-up, with no tumor progression observed. In the third year of treatment, patients received EVX-01 as stand-alone therapy.
The data will be presented at the European Society for Medical Oncology Congress 2026 in Madrid, Spain, from October 23-27, 2026. The presentation is scheduled for Friday at 12:00-12:45 CET.
The company previously reported two-year data in 2025 showing a 75% Objective Response Rate with 25% of patients obtaining a complete response. At two years, 92% of patients were still responding with no relapses observed.
The phase 2 trial investigated EVX-01 in patients with advanced melanoma. Each patient received a vaccine designed with Evaxion’s AI-Immunology platform and manufactured based on their individual biology. During the first two years, patients received EVX-01 in combination with Merck’s pembrolizumab. Six out of 12 responders continued in the trial’s one-year extension, receiving EVX-01 as stand-alone therapy.
The two-year data showed 54% of patients had a deepened response following initiation of EVX-01 treatment. Tumor reduction in target lesions was observed in 15 out of 16 patients enrolled in the trial. EVX-01 induced an immune response in all patients, with 86% of vaccine neoantigens generating specific T-cell responses at two-year follow-up.
Evaxion will host a webinar on October 29, 2026, at 15:30 CET featuring trial investigator Professor Muhammad Adnan Khattak.
EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancer tumors and is currently being evaluated as a treatment of advanced melanoma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
COPENHAGEN - Evaxion A/S (NASDAQ:EVAX) announced three-year clinical data from its phase 2 trial of personalized cancer vaccine EVX-01 in patients with advanced melanoma, according to a press release statement.
All patients at three-year follow-up maintained clinical responses observed at two-year follow-up, with no tumor progression observed. In the third year of treatment, patients received EVX-01 as stand-alone therapy.
The data will be presented at the European Society for Medical Oncology Congress 2026 in Madrid, Spain, from October 23-27, 2026. The presentation is scheduled for Friday at 12:00-12:45 CET.
The company previously reported two-year data in 2025 showing a 75% Objective Response Rate with 25% of patients obtaining a complete response. At two years, 92% of patients were still responding with no relapses observed.
The phase 2 trial investigated EVX-01 in patients with advanced melanoma. Each patient received a vaccine designed with Evaxion’s AI-Immunology platform and manufactured based on their individual biology. During the first two years, patients received EVX-01 in combination with Merck’s pembrolizumab. Six out of 12 responders continued in the trial’s one-year extension, receiving EVX-01 as stand-alone therapy.
The two-year data showed 54% of patients had a deepened response following initiation of EVX-01 treatment. Tumor reduction in target lesions was observed in 15 out of 16 patients enrolled in the trial. EVX-01 induced an immune response in all patients, with 86% of vaccine neoantigens generating specific T-cell responses at two-year follow-up.
Evaxion will host a webinar on October 29, 2026, at 15:30 CET featuring trial investigator Professor Muhammad Adnan Khattak.
EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancer tumors and is currently being evaluated as a treatment of advanced melanoma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
c8037f2564· 2026-10-19 16:31 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前